Conferences Mind conferences are accredited with Continuing Professional Development (CPD) and Continuing Education (CE), Continuing Medical Education (CME) credits respectively. This is the best platform of the worldwide Conferences, Symposia, Workshops and Exhibitions, include all major science (Medical, Clinical, Pharma, Life Science), Technology (Robotics, Mechatronics), Business Management and Engineering.

Welcome To
Global Webinar on

Pharmacology and Drug Discovery

THEME: Current Research & Future of Drug Development
November 15-16, 2021

About Pharmacology and Drug Discovery

Global Webinar on Pharmacology and Drug Discovery”, is scheduled during November 15-16, 2021. Global Pharmacology 2021 runs with the theme “Current Research & Future Of Drug Development”. We are grinning to welcome all the leading researchers, delegates, scientists, scholars, and professors to take part in this approaching conference to witness precious scientific discussions and bestow to the future improvement in the field of Pharmacology and Drug Discovery. This Conference will prominence on the informative research toward its impact on clinical outcomes, through poster and oral demonstrations, educational workshop sessions, and noteworthy plenary presentations. Global Pharmacology 2021 is a perfect podium to find out how Pharmacology and Drug Discovery. Global Pharmacology Conference will mainly highlight the recent matters during the event, which reflect present education, developments, research, and innovations globally in the field of Pharmacology and Drug Discovery

Read more

Scientific Sessions

Track 1. Pharmacology:

Pharmacology is the study of the body's reaction to drugs; it is the science of what is happening to your body and to the drug itself. The role of pharmacology is to understand why these changes are happening, allowing us to develop better drugs. Pharmacology integrates the knowledge of many disciplines, including

  • Medicine
  • Pharmacy
  • Dentistry
  • Nursing
  • Veterinary medicine

Pharmacology is a separate discipline in the health sciences.

Track 2: Drug Discovery and Development:

Drug discovery and development together are the complete process of identifying a new drug and bringing it to market. Discovery may involve screening of chemical libraries, identification of the active ingredient from a natural remedy or design resulting from an understanding of the target. Development includes studies on microorganisms and animals, clinical trials and ultimately regulatory approval. There are a multitude of barriers and difficulties that contribute to the minimal success rate within the drug development process, starting with our level of knowledge and understanding of disease states.

Track 3: Drug Metabolism

Read more

Tracks and Key Topics

  • Track 1 : Pharmacology
  • Track 2 : Drug Discovery and Development
  • Track 3 : Drug Metabolism
  • Track 4 : Preclinical Research
  • Track 5 : Pharmacokinetics
  • Track 6 : Structure-Based Drug Design
  • Track 7 : Artificial Intelligence
  • Track 8 : Novel Antibiotics
  • Track 9 : Proteomics
  • Track 10 : Clinical Pharmacology
  • Track 11 : Drug Tolerance

Read more

Organizing Committee Member

Paul Millner
Sergey Suchkov
Daniela Monti
Mino R. Caira

Speaker

Paul T E Cusack
 Wei Ling Huang
Shyamapada Mandal
 Jyotirmoi Aich
Sergey Suchkov
 Ozan Emre EYUPOGLU
F. Marotta
Zuo-cheng Qiu
Arturo Solis Herrera
Roohi Naaz Shaikh

Market Research

The global pharmaceuticals market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, according to a recent pharma market research report by The Business Research Company.

This is an accelerated pace compared to 5.2% for the years before 2017, but is slower than the other two large healthcare segments, medical equipment and healthcare services. Healthcare as a whole is growing at over 7% year on year. Part of the explanation for the relatively slow current growth of the pharma market is that the launch of major new products has slowed and that companies are restricting their R&D investment. For example, despite the huge potential for any effective and safe new drug for treating Alzheimer’s disease, Pfizer has ended its Alzheimer’s research program while AstraZeneca and GSK have cut back. High failure rates, the $2 billion average cost of developing a new drug, and falling returns on investment — down from 10.1% a year in 2010 to 3.2% in 2017 for the big pharma companies, according to Deloitte’s — are restraining the launch of high-priced new breakthrough drugs such as those that boosted the market in earlier years.

Read more

Media Partner

Doctorama
Pharmiweb.com
Pharma Times
Pharma World